• LAST PRICE
    11.8600
  • TODAY'S CHANGE (%)
    Trending Up0.1700 (1.4542%)
  • Bid / Lots
    11.7300/ 1
  • Ask / Lots
    11.8700/ 1
  • Open / Previous Close
    11.5900 / 11.6900
  • Day Range
    Low 11.4633
    High 12.0650
  • 52 Week Range
    Low 7.3200
    High 32.8990
  • Volume
    6,524
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 11.69
TimeVolumeIPSC
09:39 ET38011.59
09:41 ET113912
09:45 ET10011.8
09:50 ET20011.7
10:03 ET90011.9
10:06 ET10012
10:08 ET20012.04
10:10 ET40011.95
10:12 ET10011.95
10:17 ET90011.86
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIPSC
Century Therapeutics Inc
688.0M
-3.3x
---
United StatesFHTX
Foghorn Therapeutics Inc.
690.4M
-6.0x
---
United StatesSAVA
Cassava Sciences Inc
701.4M
-12.0x
---
United StatesSTOK
Stoke Therapeutics Inc
658.0M
-7.3x
---
United StatesNWBO
Northwest Biotherapeutics Inc
659.4M
3.7x
---
United StatesALVR
Allovir Inc
720.3M
-2.2x
---
As of 2022-08-08

Company Information

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The Company's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.

Contact Information

Headquarters
3675 Market StPHILADELPHIA, PA, United States 19104
Phone
215-981-4000
Fax
302-655-5049

Executives

Independent Chairman of the Board
Joseph Jimenez
President, Chief Executive Officer, Director
Osvaldo Flores
President - Research and Development
Hyam Levitsky
Chief Operations Officer
Adrienne Farid
Chief Technology Officer
Gregory Russotti

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$688.0M
Revenue (TTM)
$1.1M
Shares Outstanding
58.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.58
Book Value
$7.20
P/E Ratio
-3.3x
Price/Sales (TTM)
650.2
Price/Cash Flow (TTM)
---
Operating Margin
-10,799.34%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.